Danaparoid
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a602007 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
  (what is this?)
|
|
Danaparoid sodium (Orgaran) is an anticoagulant that works by inhibiting activated factor X (factor Xa).
Danaparoid is a heparinoid but considered to be a low molecular weight heparin by some sources. However it is chemically distinct from heparin, has different protein binding properties and thus has little cross-reactivity in heparin-intolerant patients.
It consists of a mixture of heparan sulfate, dermatan sulfate, and chondroitin sulfate.
It is used to prevent deep venous clots, particularly in situations with a high risk of clot formation, such as after hip surgery.
It is also used as a heparinoid substitute in heparin-induced thrombocytopenia (HIT) which may otherwise cause paradoxical thrombosis. Danaparoid is used for thrombosis prophylaxis and treatment in heparin-induced thrombocytopenia patients, although cross-reactivity with heparin-induced antibodies can occur in 10–20% of the patients (ESRA). It has been proposed for use in Kasabach-Merritt syndrome.
On August 14, 2002, this drug was withdrawn by Organon International. Due to a shortage in drug substance, the manufacturer discontinued providing the medication in the United States. It is available in several other countries.
On the Schering-Plough website, Orgaran is described as "Marketed outside the U.S."
...
Wikipedia